NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Benefytt Technologies, Inc. (NasdaqGS - BFYT), Spring Bank Pharmaceuticals, Inc. (NasdaqGS - SBPH), Jernigan Capital, Inc. (NYSE - JCAP)

BALA CYNWYD, PA / ACCESSWIRE / August 10, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

Benefytt Technologies, Inc. (NASDAQGS:BFYT)

Under the terms of the agreement, Benefytt shareholders will receive only $31.00 in cash for each share of Benefytt they own. The investigation concerns whether the Benefytt Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Madison Dearborn is underpaying for the Company. For example, the average twelve-month analyst price target is $35.88, with a high target of $45.00 per share.

Additional information can be found at http://www.brodskysmith.com/cases/benefytt-technologies-inc-nasdaqgs-bfyt/, or call 877-534-2590. No cost or obligation to you.

Jernigan Capital, Inc. (NYSE:JCAP)

Under the terms of the agreement, Jernigan Capital shareholders will receive only $17.30 for each share of Jernigan Capital they own. The investigation concerns whether the Jernigan Capital Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether NexPoint is underpaying for the Company. For example, the deal price is well off Jernigan Capital's 52-week high of $20.66 a share.

Additional information can be found at http://www.brodskysmith.com/cases/jernigan-capital-inc-nyse-jcap/, or call 877-534-2590. No cost or obligation to you.

Spring Bank Pharmaceuticals, Inc. (NASDAQGS:SBPH)

Under the terms of the share exchange agreement, Spring Bank shareholders will be significantly diluted, holding only approximately 38.8% of the combined company, and receiving two Contingent Value Rights ("CVR") with respect to certain Spring Bank programs. The investigation concerns whether the Spring Bank Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.

Additional information can be found at http://www.brodskysmith.com/cases/spring-bank-pharmaceuticals-inc-nasdaqgs-sbph/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC